Table 1.
Demographics of the EPD and Control Groups
| EPD Group, N (%) |
Control Group, N (%) |
P Value |
|
|---|---|---|---|
| Total patients | 18 | 18 | NS |
| Number of males | 14 (78) | 14 (78) | NS |
| Age at intervention (years old) | 73 ±7 | 73 ±7 | NS |
| Caucasian | 18 (100) | 18 (100) | NS |
| Risk factors | |||
| Family history of CAD | 10 (56) | 14 (78) | NS |
| Smoking | 13 (72) | 5 (28) | .01 |
| Hypertension | 17 (945) | 16 (89) | NS |
| Chronic renal insufficiency | 18 (100) | 18 (100) | NS |
| Diabetes | 9 (50) | 9 (50) | NS |
| Hyperlipidemia | 16 (89) | 14 (78) | NS |
| CAD | 14 (78) | 12 (67) | NS |
| PAD | 7 (39) | 15 (83) | .02 |
| Stroke | 5 (28) | 6 (33) | NS |
| Carotid disease | 7 (39) | 6 (33) | NS |
| Baseline statin use | 14 (78) | 11 (61) | NS |
| High proteinuria | 8 (44) | 8 (44) | NS |
| Indications | |||
| Chronic renal insufficiency | 14 (78) | 13 (72) | NS |
| Hypertension | 4 (22) | 5 (28) | NS |
| Length of follow-up (months) | 24 ± 17 | 25 ± 19 | NS |
Abbreviations: CAD, coronary artery disease; PAD, peripheral artery disease; NS, not significant EPD, embolic protection device.